Dietary Recommendations for the Management of Gastrointestinal Symptoms in Patients Treated with GLP-1 Receptor Agonist
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
GLP-1 receptor agonist (GLP-1RA) have been developed to address the global burden of obesity and are renowned for their safety and efficacy. These medications influence hunger and satiety, reducing energy intake and promoting weight loss. Despite their benefits, GLP-1RAmay cause a slowed gastric emptying, leading to gastrointestinal symptoms. This study examines how food properties and meal composition affect these symptoms. Dietary recommendations are provided, particularly for evening meals, focusing on how different foods and nutrients can influence the rate of gastric emptying, to improve patient compliance and prevent interruption in weight loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Foods with lower viscosity (i.e., that flow easily), fewer calories, lower glycemic index, and higher water content (e.g., certain fruits and vegetables and fruits) can facilitate faster gastric emptying [141].”
From Nutritional priorities to support GLP ‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society (2025) · cites this paper as [141]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients accustomed to consuming large volumes of low-energy-density foods are likely to exacerbate GLP-1-induced gastric stasis and postprandial discomfort, supporting a shift toward nutrient-dense, lower-volume feeding patterns during the titration phase [27,33,37].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When a patient receiving a high-dose GLP-1 RA consumes a high-fat meal, the combined effect of pharmacological and endogenous lipid-mediated signaling can produce profound gastric stasis [27,33].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Foods high in protein or fat can further slow gastric emptying, which can promote weight reduction and metabolism but also worsen constipation, potentially requiring temporary limitation of these foods [141].”
From Nutritional priorities to support GLP ‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society (2025) · cites this paper as [141]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GI side effects—including nausea, vomiting, bloating, and diarrhea—are profoundly dose-dependent and frequently exacerbated by specific macronutrient profiles [27,33].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [33]
Experimental — accuracy not yet measured
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · cited 1×
“9 It is released in response to meal intake leading to increased satiety and better glucose metabolism regulation.”
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970 · cited 1×
“13,15 Liraglutide , the first GLP-1RAs approved for weight management, acts as a long-acting agonist on its receptor, reducing appetite, delaying gastric emptying, and increasing pancreatic insulin secretion.”
Glucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543
Sodhi, M., Rezaeianzadeh, R., Kezouh, A., & Etminan, M. (2023) · JAMA · doi:10.1001/jama.2023.19574 · Cited by 471 · cited 1×
“8,37,38 If gastrointestinal adverse events occur, clinicians should prolong the titration period or avoid dose increases until the effects subside.”
Friedrichsen, M., Breitschaft, A., Tadayon, S., Wizert, A., & Skovgaard, D. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14280 · Cited by 427 · cited 1×
“17 An increased incidence of gallstones has been reported in patients treated with Liraglutide, along with a potential association between mild pancreatitis and rapid weight loss.”
Bettge, K., Kahle, M., Abd El Aziz, M. S., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12824 · Cited by 374 · cited 2×
“11,18 Therefore, understanding the mechanisms underpinning these issues is crucial.”
Advances in the physiology of gastric emptying
Goyal, R. K., Guo, Y., & Mashimo, H. (2019) · Neurogastroenterology & Motility · doi:10.1111/nmo.13546 · Cited by 369
Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., Castro, A., Cebrián-Cuenca, A., de Torres-Sánchez, A., García-de-Lucas, M. D., Núñez, J., Obaya, J. C., Soler, M. J., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010145 · Cited by 358 · cited 3×
“8 In this regard, a group of medical experts, including endocrinologists, nephrologists, general practitioners, cardiologists, internal medicine specialists, and nurses, recently have developed dietary and behavioral guidelines to prevent or minimize gastrointestinal effects and avoid medication…”
Janssen, P., Vanden Berghe, P., Verschueren, S., Lehmann, A., Depoortere, I., & Tack, J. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04609.x · Cited by 348
Emerging role of GLP-1 agonists in obesity: A comprehensive review of randomised controlled trials
Popoviciu, M.-S., Păduraru, L., Yahya, G., Metwally, K., & Cavalu, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310449 · Cited by 280 · cited 1×
“2,3 There are different types of drugs that have been developed through the years; among these, GLP-1 receptor agonists (GLP-1RAs) are known for their safety and efficacy 4 due to their ability to act at the hypothalamic influencing hunger and fullness, and consequently reducing caloric intake.”
Liu, L., Chen, J., Wang, L., Chen, C., & Chen, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1043789 · Cited by 258 · cited 2×
“8,37,38 If gastrointestinal adverse events occur, clinicians should prolong the titration period or avoid dose increases until the effects subside.”
Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity
Maselli, D. B., & Camilleri, M. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_496 · Cited by 248 · cited 1×
“6 While GLP-1 has a brief half-life due to rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4), GLP-1RAs have been developed with a prolonged half-life.”
Wharton, S., Davies, M., Dicker, D., Lingvay, I., Mosenzon, O., Rubino, D. M., & Pedersen, S. D. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2021.2002616 · Cited by 236 · cited 2×
“39 If side effects appear when transitioning to a higher dose, the recommendation is to revert to the previous dose and then gradually increase it, or to establish a maximum tolerated dose for maintenance.”
Glucagon‐like peptide‐1 receptor agonists in type 2 diabetes treatment: are they all the same?
Gentilella, R., Pechtner, V., Corcos, A., & Consoli, A. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3070 · Cited by 227 · cited 1×
“14 Human GLP-1 analogues are modified versions of the GLP-1 peptide, 15,16 available in several sizes and structures, influencing their mechanism of action and half-life.”
Guideline Recommendations for Obesity Management
Ryan, D. H., & Kahan, S. (2018) · Medical Clinics of North America · doi:10.1016/j.mcna.2017.08.006 · Cited by 221
Neeland, I. J., Marso, S. P., Ayers, C. R., Lewis, B., Oslica, R., Francis, W., Rodder, S., Pandey, A., & Joshi, P. H. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00179-0 · Cited by 202 · cited 2×
“10,11 Semaglutide shares 94% structural homology with native GLP-1.”
Zhu, Y., Hsu, W. H., & Hollis, J. H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067482 · Cited by 164 · cited 1×
“30 Recent research conducted by Liu et al supports this thesis.”
Yu, K., Ke, M., Li, W., Zhang, S., & Fang, X. (2014) · PubMed · doi:10.6133/apjcn.2014.23.2.01 · Cited by 162 · cited 1×
“36”
Mechanisms, physiology, and recent research progress of gastric emptying
Liu, W., Jin, Y., Wilde, P. J., Hou, Y., Wang, Y., & Han, J. (2020) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2020.1784841 · Cited by 122
Newer GLP-1 receptor agonists and obesity-diabetes
Brown, E. E., Cuthbertson, D. J., & Wilding, J. P. H. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.009 · Cited by 110 · cited 1×
“14 Human GLP-1 analogues are modified versions of the GLP-1 peptide, 15,16 available in several sizes and structures, influencing their mechanism of action and half-life.”
Modern vision of the Mediterranean diet
Kiani, A. K., Medori, M. C., Bonetti, G., Aquilanti, B., Velluti, V., Matera, G., Iaconelli, A., Stuppia, L., Connelly, S., Herbst, K. L., et al. (2022) · Journal of preventive medicine and hygiene · doi:10.15167/2421-4248/jpmh2022.63.2s3.2745 · Cited by 105
Camps, G., Mars, M., de Graaf, C., & Smeets, P. A. M. (2016) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.115.129064 · Cited by 99 · cited 1×
“29 This phenomenon could regulate the postprandial glycemic response and prolong the sense of satiety, as food needs to be digested for a longer period to reduce its viscosity.”
Effect of temperature and chemical composition on processed cheese apparent viscosity
Dimitreli, G., & Thomareis, A. S. (2003) · Journal of Food Engineering · doi:10.1016/j.jfoodeng.2003.10.008 · Cited by 82
Holtmann, G., & Talley, N. (2014) · Best practice & research. Clinical gastroenterology · doi:10.1016/j.bpg.2014.10.001 · Cited by 62 · cited 1×
“23 Conditions such as gastroesophageal reflux, gastritis, allergies, and certain drugs may also significantly affect digestion 24 as well as emotions such as anger, anxiety, and stress, 25 revealing the role of the gut as a “second brain”.”
Huber, H., Schieren, A., Holst, J. J., & Simon, M.-C. (2024) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2024.01.007 · Cited by 62
Zhou, S.-Y., Lu, Y.-X., Yao, H., & Owyang, C. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00309.2006 · Cited by 53 · cited 1×
“20,21 Hormones like cholecystokinin and GLP-1 may slow down gastric emptying by acting on the gastric inhibitory vagal motor circuit, while hormones like ghrelin and motilin can speed it by stimulating the gastric excitatory vagal motor circuit.”
Maurer, A. H. (2012) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2011.10.001 · Cited by 53 · cited 1×
“26 The pressure disparity between the stomach and the duodenum can also affect the speed of emptying of liquid foods.”
Purnell, J. Q., & le Roux, C. W. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15478 · Cited by 40
Radioisotopic assessment of gastric emptying of solids in elderly subjects
Brogna, A., Loreno, M., Catalano, F., Bucceri, A. M., Malaguarnera, M., Muratore, L. A., & Travali, S. (2006) · Aging Clinical and Experimental Research · doi:10.1007/bf03324849 · Cited by 39
Wan, J., Ferrari, C., & Tadros, M. S. (2024) · Gastroenterology Insights · doi:10.3390/gastroent15010014 · Cited by 34
Masson, L., Rosenthal, A., Calado, V. M. D. A., Deliza, R., & Tashima, L. (2010) · LWT · doi:10.1016/j.lwt.2010.07.012 · Cited by 32 · cited 1×
“34 As for fats, their high molecular cohesion results in high viscosity.”
Rahmati, N. F., Tehrani, M. M., Daneshvar, K., & Koocheki, A. (2014) · Food Biophysics · doi:10.1007/s11483-014-9356-1 · Cited by 28
Understanding the mechanism of high viscosity food delaying gastric emptying
Liu, W., Jin, W., Wilde, P. J., Jin, Y., Pan, Y., & Han, J. (2024) · Food & Function · doi:10.1039/d4fo00319e · Cited by 23 · cited 2×
“31 They utilized nutritious model meals based on peanut butter, with viscosity manipulated through the addition of guar gum, to investigate the effects of food viscosity on gastric emptying, gastric motility, and physiological responses in human volunteers.”
The role of food structure in gastric-emptying rate, absorption and metabolism
Mackie, A. R. (2023) · Proceedings of The Nutrition Society · doi:10.1017/s0029665123003609 · Cited by 17 · cited 2×
“28 Viscosity is another crucial property with high viscosity inhibiting gastric emptying and affecting transit time in the digestive tract; it is closely related to food digestion regulation, nutrient absorption, and physiological responses such as glycemic response and appetite regulation.”
Dericioglu, D., Oldham, S. N., Methven, L., Shafat, A., & Clegg, M. (2023) · Appetite · doi:10.1016/j.appet.2023.106982 · Cited by 16 · cited 2×
“33 Concerning the viscosity of cheese, it decreases as the temperature rises due to a decrease in the force of attraction between the molecules.”
[Relationship between gastric motility and the pathophysiology of GERD].
Kamiya, T., Adachi, H., & Joh, T. (2007) · PubMed · Cited by 3
Research works printed but not linked: 3
- Travagli, 2006, Annu Rev Physiol, 68, 279, 10.1146/annurev.physiol.68.040504 · doi:10.1146/annurev.physiol.68.040504
- Kamiya, 2007, Nihon Rinsho, 65, 836
- 2011, Healthy Eating Plate, Chan School of Public Health
Cited by
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.04.023 · Cited by 154
“Foods high in protein, fat, or fiber can further slow gastric emptying, which can be helpful for weight reduction and metabolism but can also worsen constipation, potentially requiring temporary limitation of these foods [132].”
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · Obesity · doi:10.1002/oby.24336 · Cited by 143
“Dietary recommendations should be adjusted based on the rate of weight reduction, nutrient status, individual tolerance, and treatment response.”
Rosen, C. J., & Ingelfinger, J. R. (2026) · New England Journal of Medicine · doi:10.1056/nejmra2500106 · Cited by 135
Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment
Sannidhi, D., Abeles, R., Andrew, W., Bonnet, J. P., Vitale, K., Niranjan, V., Gulati, M., Pauly, K., Moran, R., Alexander, L., et al. (2025) · Nutrients · doi:10.3390/nu17142382 · Cited by 29
“While fiber is a nutrient of concern and intake should be encouraged, higher fiber intake can sometimes exacerbate side effects [101].”
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100181 · Cited by 28
Metadata
- Authors
- Gentinetta, S., Sottotetti, F., Manuelli, M., & Cena, H.
- Affiliations
- Novo Nordisk (Italy) (IT)
- University of Pavia (IT)
- Istituti Clinici Scientifici Maugeri (IT)
- Corresponding author
- Sottotetti, Francesca
- Venue
- Diabetes, Metabolic Syndrome and Obesity
- Publisher
- Informa UK Limited
- Published
- 2024-12
- Volume
- Volume 17
- Pages
- 4817-4824
- ISSN
- 1178-7007 (ISSN-L)
- PMC
- PMC11668918
- OpenAlex
- W4405544542
- Cited by
- 32
- References
- 38
- Citations by year
- 2026: 18 · 2025: 14
- FWCI
- 9.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Diabetes Metabolic Syndrome and Obesity (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- GLP-1 receptor agonists, gastrointestinal symptoms, delayed gastric emptying, dietary recommendations, meal composition, food properties, dinner, weight loss, obesity, satiety, medication adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
